🟢 Tvardi Therapeutics is trading 10% up in pre-market with no confirmed catalyst

Tvardi Therapeutics is trading 10.21% higher at $1.40, with no confirmed catalyst for September 28 identified.

• The price is versus the September 25 close of $1.27; shares rose 19.81% that day.
• The latest company news was a September 24 report of preclinical TTI-101 data in a mouse model, not a new September 28 announcement.
• Broader market indicators were lower, and pre-market volume data was unavailable.